Furthermore, our study demonstrates that inhibiting renal MDK expression alleviates cognitive impairment and reduces microglial activation, highlighting the therapeutic potential of targeting the MDK‐LRP1 pathway in AKI‐related cognitive decline. This evidence concerns the gene MDK and acute kidney injury.